Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03455556 · ClinicalTrials.gov registry record · Phase 1
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03455556: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT03455556 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03455556, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other places in the body. Monoclonal antibodies, such as anetumab ravtansine and atezolizumab, may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Atezolizumab
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Anetumab Ravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2020-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03455556
The ClinicalTrials.gov registry entry for NCT03455556 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03455556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03455556 about?
NCT03455556 is a clinical study titled "Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer". This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other places in the body. Monoclonal antibodies, such as anetumab ravtansine an...
What is the current status of trial NCT03455556?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-08-10. Estimated completion is 2020-01-07.
What interventions are being tested in trial NCT03455556?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Anetumab Ravtansine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03455556?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.